GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 3 380 JPY 5.13% Market Closed
Market Cap: 169.4B JPY
Have any thoughts about
GNI Group Ltd?
Write Note
GNI Group Ltd
/
Balance Sheet
/
Cash Equivalents

GNI Group Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GNI Group Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
GNI Group Ltd
TSE:2160
Cash Equivalents
¥14B
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
11%
PeptiDream Inc
TSE:4587
Cash Equivalents
¥50.4B
CAGR 3-Years
60%
CAGR 5-Years
43%
CAGR 10-Years
31%
Takara Bio Inc
TSE:4974
Cash Equivalents
¥40B
CAGR 3-Years
7%
CAGR 5-Years
17%
CAGR 10-Years
8%
Pharma Foods International Co Ltd
TSE:2929
Cash Equivalents
¥11.8B
CAGR 3-Years
2%
CAGR 5-Years
27%
CAGR 10-Years
22%
S
StemRIM Inc
TSE:4599
Cash Equivalents
¥8.4B
CAGR 3-Years
-6%
CAGR 5-Years
27%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Cash Equivalents
¥5.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
169.2B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 956.28 JPY
Undervaluation 32%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is GNI Group Ltd's Cash Equivalents?
Cash Equivalents
14B JPY

Based on the financial report for Sep 30, 2024, GNI Group Ltd's Cash Equivalents amounts to 14B JPY.

What is GNI Group Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
11%

Over the last year, the Cash Equivalents growth was -23%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.